Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5385111 | 0.92 | LTA4H (0.48) | LMNAGAACYP1A2CYP2C9PKM | |
| SCHEMBL14366360 | 0.92 | LTA4H (0.48) | LMNAGAACYP1A2CYP2C9PKM | |
| SCHEMBL25325632 | 0.86 | LMNA (0.48) | LMNAMTNR1AMTNR1BGAACYP1A2 | |
| SCHEMBL1453272 | 0.85 | CA4 (0.48) | LMNAMTNR1AMTNR1BGAACYP1A2 | |
| SCHEMBL11210416 | 0.84 | LMNA (0.47) | LMNAMTNR1AMTNR1BGAACYP1A2 | |
| SCHEMBL1252991 | 0.82 | LMNA (0.45) | LMNAMTNR1AMTNR1BGAACYP1A2 | |
| SCHEMBL10764289 | 0.82 | LMNA (0.45) | LMNAMTNR1AMTNR1BGAACYP1A2 | |
| SCHEMBL19714108 | 0.82 | LMNA (0.45) | LMNAMTNR1AMTNR1BGAACYP1A2 | |
| SCHEMBL17892009 | 0.82 | LMNA (0.45) | LMNAMTNR1AMTNR1BGAACYP1A2 | |
| SCHEMBL17901028 | 0.82 | LMNA (0.45) | LMNAMTNR1AMTNR1BGAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230094112-A1 | METHODS TO CONTROL INFECTION USING NEW GENERATION SMALL MOLECULE GROWTH INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2023-03-30 | — | — | US | disclosed |
| US-11478454-B2 | Methods to control infection using new generation small molecule growth inhibitors | OHIO STATE INNOVATION FOUNDATION (US) | 2022-10-25 | — | — | US | disclosed |
| US-20200405691-A1 | METHODS TO CONTROL INFECTION USING NEW GENERATION SMALL MOLECULE GROWTH INHIBITORS | OHIO STATE INNOVATION FOUNDATION | 2020-12-31 | — | — | US | disclosed |
| US-20110184418-A1 | Unsealed, Non-Colloidal Radiopharmaceutical Compositions and Methods for Treatment of Abnormal Tissue | SARI ASHER, LLC | 2011-07-28 | — | — | US | disclosed |
| WO-2011035024-A2 | UNSEALED, NON-COLLOIDAL RADIOPHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF ABNORMAL TISSUE | SARI ASHER LLC (US) | 2011-03-24 | — | — | WO | disclosed |
| EP-1315517-B1 | MIMETIC PEPTIDES FOR EPITOPE OF APOLIPOPROTEIN B-100, CONCATEMER AND MODIFIED PEPTIDES THEREOF, AND THE VACCINE COMPOSITION COMPRISING THE SAME | KIM HYO JOON (KR) | 2010-10-20 | — | — | EP | disclosed |
| US-20080138728-A1 | LATENT ELECTROSTATIC IMAGE BEARING MEMBER, AND IMAGE FORMING APPARATUS, IMAGE FORMING METHOD AND PROCESS CARTRIDGE USING THE SAME | RICOH COMPANY, LTD. (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20060025390-A1 | Treatment of hormone allergy and related symptoms and disorders | ROBY RUSSELL R | 2006-02-02 | — | — | US | disclosed |
| WO-2005105106-A2 | HORMONE TREATMENT OF MACULAR DEGENERATION | ROBY RUSSELL R (US) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005105107-A2 | HORMONE TREATMENT OF MULTIPLE SCLEROSIS | ROBY RUSSELL R (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050239757-A1 | Hormone treatment of macular degeneration | ROBY RUSSELL R | 2005-10-27 | — | — | US | disclosed |
| US-20050239758-A1 | Hormone treatment of multiple sclerosis | ROBY RUSSELL R | 2005-10-27 | — | — | US | disclosed |
| EP-1315517-A4 | MIMETIC PEPTIDES FOR EPITOPE OF APOLIPOPROTEIN B-100, CONCATEMER AND MODIFIED PEPTIDES THEREOF, AND THE VACCINE COMPOSITION COMPRISING THE SAME | KIM HYO JOON (KR) | 2005-02-09 | — | — | EP | disclosed |
| US-6825318-B2 | VACCINE FOR OBESITY THERAPY; HYBRID POLYPEPTIDES | Kim, Hyo-Joon (KR) | 2004-11-30 | — | — | US | disclosed |
| US-20030211997-A1 | Mimetic peptides for an epitope of apolipoprotein B-100, concatemers of the peptides, and modified peptides, and compositions comprising the same | KIM, HYO-JOON (KR) | 2003-11-13 | — | — | US | disclosed |
| EP-1315517-A1 | MIMETIC PEPTIDES FOR EPITOPE OF APOLIPOPROTEIN B-100, CONCATEMER AND MODIFIED PEPTIDES THEREOF, AND THE VACCINE COMPOSITION COMPRISING THE SAME | Kim, Hyo-Joon (KR) | 2003-06-04 | — | — | EP | disclosed |
| WO-2003024468-A1 | SUBSTANCES EXTRACTED FROM CORN WHICH CAN INHIBIT THE ACTIVITIES OF AMYLASE, PHARMACEUTICAL COMPOSITIONS AND FOOD ADDITIVES CONTAINING THE SAME EXTRACTS FOR TREATMENT OR PREVENTION OF OBESITY AND DIABETES MELLITUS, AND PROCESSES FOR THEIR PREPARATIONS | BIONEER CORPORATION (KR) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002020040-A1 | MIMETIC PEPTIDES FOR EPITOPE OF APOLIPOPROTEIN B-100, CONCATEMER AND MODIFIED PEPTIDES THEREOF, AND THE VACCINE COMPOSITION COMPRISING THE SAME | KIM HYO JOON (KR) | 2002-03-14 | — | — | WO | disclosed |
| WO-1993011669-A1 | USE OF 3-PHENYLURACIL DERIVATIVES FOR THE DESICCATION AND ABSCISSION OF PLANT PARTS | BASF AKTIENGESELLSCHAFT (DE) | 1993-06-24 | — | — | WO | disclosed |
| US-4388081-A | CONTAINING PHENOXYALCOHOL AS ANTINKNOCK ADDITIVE | PHILLIPS PETROLEUM COMPANY (US) | 1983-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478454-B2 | Methods to control infection using new generation small molecule growth inhibitors | SMURF1, SMURF2, SMYD3 | LMNA 4633/4885MTNR1A 3180/4885MTNR1B 3199/4885 |
| US-20230094112-A1 | METHODS TO CONTROL INFECTION USING NEW GENERATION SMALL MOLECULE GROWTH INHIBITORS | SMURF1, SMURF2, SMYD3 | LMNA 4604/4885MTNR1A 3213/4885MTNR1B 3201/4885 |
| US-20200405691-A1 | METHODS TO CONTROL INFECTION USING NEW GENERATION SMALL MOLECULE GROWTH INHIBITORS | SMURF1, SMURF2, SMYD3 | LMNA 4633/4885MTNR1A 3180/4885MTNR1B 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.